Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

209.09 +0.78 (+0.38%)
Streaming Delayed Price Updated: 11:10 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
News headline image
3 Dividend Stocks That Are No-Brainer Buys Right Now ↗
Via The Motley Fool
News headline image
Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform ↗
Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low. 
Via Benzinga
Topics ETFs Stocks
News headline image
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang ↗
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts. 
Via Benzinga
News headline image
Wall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company ↗
This virtually unknown company has been paying a continuous dividend for six decades longer than any other U.S. stock. 
Via The Motley Fool
News headline image
A Closer Look at Johnson & Johnson's Options Market Dynamics ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for Johnson & Johnson ↗
 
Via Benzinga
News headline image
What's a Fair Price to Buy Johnson & Johnson Stock? ↗
Via The Motley Fool
News headline image
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says ↗
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026. 
Via Benzinga
News headline image
Johnson & Johnson Sues Samsung Bioepis Over Alleged Biosimilar Agreement Breach For Its Flagship Psoriasis Drug ↗
Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® biosimilar, potentially harming market competition. 
Via Benzinga
Topics Lawsuit
News headline image
3 Dividend-Paying Stocks Bucking the Market’s Trend
Via MarketBeat
News headline image
Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market ↗
Many analysts are feeling better about the prospects for healthcare stocks in 2025. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream ↗
Via The Motley Fool
News headline image
2 Stocks to Buy if There Is a Market Crash in 2025 ↗
Via The Motley Fool
News headline image
(JNJ) - Analyzing Johnson & Johnson's Short Interest ↗
 
Via Benzinga
News headline image
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income ↗
Via The Motley Fool
News headline image
NVIDIA's New AI System Aims To Transform Genetic Research With Unmatched Speed And Precision ↗
NVIDIA (NASDAQ: NVDA) has introduced Evo 2, an advanced artificial intelligence (AI) system aimed at transforming the field of biological research. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors. 
Via Benzinga
Topics ETFs Government World Trade
News headline image
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025. 
Via Benzinga
News headline image
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich ↗
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
News headline image
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study ↗
Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge. 
Via Benzinga
News headline image
Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead ↗
Josh Gottheimer disclosed dozens of recent stock transactions including selling Nvidia stock and buying Tesla stock. 
Via Benzinga
News headline image
Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates ↗
Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ongoing efforts to refine its medtech division. 
Via Benzinga
News headline image
Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself' ↗
 
Via Benzinga
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Via The Motley Fool
Topics Stocks
News headline image
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years ↗
On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). 
Via Benzinga
News headline image
Kenvue's Q4 Sales Miss, Margins Improve ↗
Kenvue posted mixed Q4 earnings, with in-line EPS but revenue below estimates, driven by challenges in its Skin Health and Beauty segment. 
Via The Motley Fool
Topics Earnings
News headline image
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
News headline image
What To Expect From Eli Lilly’s (LLY) Q4 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. 
Via StockStory
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
From Johnson & Johnson
Via Business Wire
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.